Soligenix Inc. is making significant strides in developing innovative therapeutics for rare diseases and public health challenges, according to recent comments by CEO Dr. Christopher Schaber. The biopharmaceutical company is pursuing a two-pronged approach that spans both specialized biotherapeutics and critical public health solutions.
In the Specialized BioTherapeutics segment, Soligenix is advancing several promising treatments. The company has completed its second Phase 3 study for HyBryte™ (SGX301), a novel photodynamic therapy targeting cutaneous T-cell lymphoma. The successful trial positions the company to seek regulatory approvals for potential worldwide commercialization.
Additional development programs include expanding synthetic hypericin into psoriasis treatment, developing an innovative innate defense regulator technology, and exploring treatments for inflammatory diseases such as oral mucositis in head and neck cancer.
The company's Public Health Solutions segment has secured over $60 million in non-dilutive U.S. government funding, underscoring the strategic importance of its research. Key programs include RiVax®, a ricin toxin vaccine candidate, and vaccine development targeting filoviruses like Marburg and Ebola, as well as a COVID-19 vaccine candidate.
Soligenix leverages its proprietary ThermoVax® heat stabilization platform technology in these vaccine development efforts, which have garnered support from significant government agencies including the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority.
The company is actively pursuing strategic opportunities and partnership discussions, with near-term milestones including a confirmatory Phase 3 trial. These efforts demonstrate Soligenix's commitment to addressing unmet medical needs across rare diseases and critical public health challenges.
